跳至主要内容
临床试验/NCT07031141
NCT07031141尚未招募不适用

Diabetes Foot Africa Region Registry

Getz Pharma0 个研究点目标入组 2,000 人开始时间: 2025年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
2,000
主要终点
Proportion of Subjects Achieving Complete Wound Healing

研究概览

简要总结

D-FAR is to gather robust data on the clinical characteristics, management, and outcomes of patients with diabetic foot complications to enhance understanding, reduce complications, and improve patient care. This will include insights into the prevalence of risk factors, adherence to treatment protocols, and the effectiveness of interventions aimed at reducing the incidence of amputations and other adverse outcomes.

详细描述

Among the various complications, those related to diabetic foot disease are associated with the highest morbidity and mortality. Diabetic foot problems are characterized by infection, ulceration and/or destruction of deep tissue in the foot and are usually associated with neurological abnormalities and varying degrees of peripheral arterial disease (PAD) in the lower limb. the purpose of collect comprehensive data on the clinical features, management strategies, and outcomes of patients with diabetic foot complications.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Male and female patients
  • Residents of participating African countries.
  • Diagnosed with diabetic foot complications (e.g., ulcers, gangrene, infection, ischemia).
  • Patients with a history of foot ulcers or amputations due to diabetes.
  • High-risk patients with peripheral neuropathy and/or peripheral arterial disease.

排除标准

  • Non-diabetic foot complications.
  • Acute traumatic injuries unrelated to diabetes.
  • Patients unwilling to provide informed consent.

结局指标

主要结局

Proportion of Subjects Achieving Complete Wound Healing

时间窗: Assessed at 3, 6, and 12 months post-enrollment

Percentage of patients with diabetic foot ulcers who achieve complete wound closure without discharge or infection as recorded during follow-up visits. Defined as complete epithelialization of the diabetic foot ulcer with no discharge or infection as assessed during clinical follow-up.

Proportion of Subjects Undergoing Amputation Due to Diabetic Foot Ulcer

时间窗: Up to 12 months from enrollment

Number of subjects requiring surgical amputation (minor or major) of the affected foot during the follow-up period

次要结局

  • Time Taken for Diabetic Foot Ulcer to Heal(Up to 12 months from enrollment)
  • Change in SINBAD Score Over Time(Baseline, 3, 6, and 12 months)
  • All-Cause Mortality Among Subjects with Diabetic Foot Ulcers(Up to 12 months from enrollment)
  • Proportion of Subjects with Peripheral Neuropathy and Peripheral Arterial Disease(At baseline)

研究者

发起方
Getz Pharma
申办方类型
Industry
责任方
Sponsor

相似试验